Answers are grounded in this paper and cite their sources.
Pruritus is a common cutaneous adverse event of immune checkpoint inhibitors (ICIs), affecting approximately 30% of patients.1 Pruritus occurs in approximately 24% of patients treated with single-agent programmed cell death protein 1 inhibitors and can significantly impair quality of life.1 Most cases occur within 3 to 10 weeks of treatment initiation and may present with or without associated primary or secondary skin changes.1 For severe cases recalcitrant to conservative therapy with topical steroids and antihistamines, steroid-sparing agents recommended by the National Comprehensive Cancer Network include dupilumab and omalizumab (ICI-Related Toxicities, v1.2026).
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: